Trimodality Therapy for Lung Cancer With Chest Wall Invasion: Initial Results of a Phase II Study Koji Kawaguchi, MD, Kohei Yokoi, MD, Hiroshi Niwa,

Slides:

Advertisements

Similar presentations

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Advertisements

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

Outcomes of Major Lung Resection After Induction Therapy for Non-Small Cell Lung Cancer in Elderly Patients Chi-Fu Jeffrey Yang, MD, Nicholas R. Mayne,

Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes Meng S. Shao, MD, Andrew T. Wong, MD,

Lymphovascular Invasion as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis Nathan M. Mollberg, DO,

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.

Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer

Thomas J. Birdas, MD, Richard P. M

Complete Metabolic Response Is Not Uniformly Predictive of Complete Pathologic Response After Induction Therapy for Esophageal Cancer Brendon M. Stiles,

Comparison of Thoracoscopic Segmentectomy and Thoracoscopic Lobectomy for Small-Sized Stage IA Lung Cancer Chenxi Zhong, MD, Wentao Fang, MD, Teng Mao,

Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Adjuvant Chemotherapy with 5-Fluorouracil and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma Jeeyun Lee, MD, Kyoung-Eun.

Clinical Prognosis of Superior Versus Basal Segment Stage I Non-Small Cell Lung Cancer Yoshinori Handa, MD, Yasuhiro Tsutani, MD, PhD, Norifumi Tsubokawa,

Long-Term Outcomes of En Bloc Resection of Non-Small Cell Lung Cancer Invading the Thoracic Inlet and Spine Elie Fadel, MD, Gilles Missenard, MD, Charles.

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes Julie E. Bauman, MD, Michael.

Trimodality Therapy for Superior Sulcus Non-Small Cell Lung Cancer: Southwest Oncology Group-Intergroup Trial S0220 Kemp H. Kernstine, MD, PhD, James.

Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J

Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases

Lobectomy in Octogenarians With Non-Small Cell Lung Cancer: Ramifications of Increasing Life Expectancy and the Benefits of Minimally Invasive Surgery

Clinical T2-T3N0M0 Esophageal Cancer: The Risk of Node Positive Disease Brendon M. Stiles, MD, Farooq Mirza, MD, Anthony Coppolino, MD, Jeffrey L. Port,

Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer Robert E. Merritt, MD, Chuong D. Hoang, MD,

Jong Ho Cho, MD, Masatsugu Hamaji, MD, Mark S. Allen, MD, Stephen D

Adil Ayub, MD, Sadiq S. Rehmani, MD, Adnan M

Importance of Ground Glass Opacity Component in Clinical Stage IA Radiologic Invasive Lung Cancer Aritoshi Hattori, MD, Takeshi Matsunaga, MD, Kazuya.

Prognostic Predictors in Non-Small Cell Lung Cancer Patients Undergoing Intentional Segmentectomy Terumoto Koike, MD, PhD, Teruaki Koike, MD, PhD, Yasushi.

Adding Radiotherapy to Adjuvant Chemotherapy Does Not Improve Survival of Patients With N2 Lung Cancer Justin A. Drake, MD, David C. Portnoy, MD, Kurt.

Philip W. Smith, MD, Hongkun Wang, PhD, Leo M. Gazoni, MD, K

Chris Dickhoff, MD, Max Dahele, MD, PhD, Sayed M

The Efficacy of Restaging Endobronchial Ultrasound in Patients With Non-Small Cell Lung Cancer After Preoperative Therapy Basil S. Nasir, MBBCh, Ayesha.

Lung Cancer Surgery in Patients With Liver Cirrhosis

Asad A. Shah, MD, Mathias Worni, MD, MHS, Christopher R

Thomas J. Birdas, MD, Richard P. M

Use of Amiodarone After Major Lung Resection

Conditional Survival After Surgical Intervention in Patients With Non-Small Cell Lung Cancer Takayuki Fukui, MD, Toshiki Okasaka, MD, Koji Kawaguchi,

Does Repeated Lung Resection Provide Long-Term Survival for Recurrent Pulmonary Metastases of Colorectal Cancer? Results of a Retrospective Japanese Multicenter.

Elliot Wakeam, MD, MPH, James P. Byrne, MD, Gail E

Docetaxel Consolidation Therapy Following Cisplatin, Vinorelbine, and Concurrent Thoracic Radiotherapy in Patients with Unresectable Stage III Non-small.

Abel Gómez-Caro, MD, Pedro Arguis, MD The Annals of Thoracic Surgery

Survival After Surgery for Pathologic Stage IA Non-Small Cell Lung Cancer Associated With Idiopathic Pulmonary Fibrosis Yuichi Saito, MD, Yasuyuki Kawai,

Recurrence and Survival After Segmentectomy in Patients With Prior Lung Resection for Early-Stage Non-Small Cell Lung Cancer Lisa M. Brown, MD, Brian.

Subcategorization of Lung Cancer Based on Tumor Size and Degree of Visceral Pleural Invasion⁎ Noriaki Sakakura, MD, Shoichi Mori, MD, Katsuhiro Okuda,

Differences in Patterns of Recurrence in Early-Stage Versus Locally Advanced Non- Small Cell Lung Cancer Feiran Lou, MD, MS, Camelia S. Sima, MD, MS,

Short-course induction chemoradiotherapy with paclitaxel for stage III non-small-cell lung cancer Thomas W Rice, MD, David J Adelstein, MD, Jay P Ciezki,

Extent of Lymphadenectomy Is Associated With Improved Overall Survival After Esophagectomy With or Without Induction Therapy Pamela Samson, MD, MPHS,

Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer Jiro Okami, MD, PhD, Yuri Ito, PhD, Masahiko.

Selective Mediastinal Lymphadenectomy for Clinico-Surgical Stage I Non–Small Cell Lung Cancer Morihito Okada, MD, PhD, Toshihiko Sakamoto, MD, PhD, Tsuyoshi.

Impact of Pulmonary Function Measurements on Long-Term Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer Mark F. Berry, MD, Chi-Fu Jeffrey.

Jonathan D. Spicer, MD, PhD, Jitesh B. Shewale, BDS, PhD, David B

Radiofrequency Ablation for Stage I Non-Small Cell Lung Cancer: Management of Locoregional Recurrence Michael Lanuti, MD, Amita Sharma, MD, Henning Willers,

Phillip G. Rowse, MD, Dawn E

Number of Metastatic Lymph Nodes in Resected Non–Small Cell Lung Cancer Predicts Patient Survival Jin Gu Lee, MD, Chang Young Lee, MD, In Kyu Park, MD,

Douglas E. Paull, MD, Glenda M. Updyke, PA-C, Michael A

Arman Kilic, BS, Matthew J. Schuchert, MD, Brian L

Subcategorization of Resectable Non-Small Cell Lung Cancer Involving Neighboring Structures Noriaki Sakakura, MD, Shoichi Mori, MD, Futoshi Ishiguro,

Prognostic Significance of Aberrant Methylation of Solute Carrier Gene Family 5A8 in Lung Adenocarcinoma Koei Ikeda, MD, PhD, Kenji Shiraishi, MD, PhD,

Prognostic Heterogeneity in Multilevel N2 Non-Small Cell Lung Cancer Patients: Importance of Lymphadenopathy and Occult Intrapulmonary Metastases Yukinori.

Preoperative Concurrent Chemoradiotherapy of S-1/Cisplatin for Stage III Non-Small Cell Lung Cancer Masafumi Yamaguchi, MD, PhD, Gouji Toyokawa, MD,

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Pneumonectomy After Chemoradiation Therapy for Non-Small Cell Lung Cancer: Does “Side” Really Matter? Anthony W. Kim, MD, L. Penfield Faber, MD, William.

Effect of Formalin Fixation on Tumor Size Determination in Stage I Non-Small Cell Lung Cancer Po-Kuei Hsu, MD, Hsu-Chih Huang, MD, Chih-Cheng Hsieh,

Mark W. Hennon, MD, Elisabeth U

Clinical Outcome After Pulmonary Resection for Lung Cancer Patients on Hemodialysis Toshiro Obuchi, MD, Wakako Hamanaka, MD, Yasuhiro Yoshida, MD, Jun.

Survival and Outcomes of Pulmonary Resection for Non-Small Cell Lung Cancer in the Elderly: A Nested Case-Control Study Robert J. Cerfolio, MD, Ayesha.

Mark I. Block, MD The Annals of Thoracic Surgery

Domenico Galetta, MD, PhD, Lorenzo Spaggiari, MD, PhD

Early Surgical Results After Pneumonectomy for Non-Small Cell Lung Cancer are not Affected by Preoperative Radiotherapy and Chemotherapy Tomas Gudbjartsson,

Phase II Study of Sequential Triplet Chemotherapy, Irinotecan and Cisplatin Followed by Amrubicin, in Patients with Extensive-Stage Small Cell Lung Cancer:

Induction Therapy Followed by Surgery for T3-T4/N0 Non-Small Cell Lung Cancer: Long-Term Results Filippo Lococo, MD, Alfredo Cesario, MD, Stefano Margaritora,

Treating Locally Advanced Disease: An Analysis of Very Large, Hilar Lymph Node Positive Non-Small Cell Lung Cancer Using the National Cancer Data Base

Presentation transcript:

Trimodality Therapy for Lung Cancer With Chest Wall Invasion: Initial Results of a Phase II Study Koji Kawaguchi, MD, Kohei Yokoi, MD, Hiroshi Niwa, MD, Yasuhisa Ohde, MD, Shoichi Mori, MD, Sakae Okumura, MD, Satoshi Shiono, MD, Hiroyuki Ito, MD, Motoki Yano, MD, Kikuo Shigemitsu, MD, Yoshinori Hiramatsu, MD, Jiro Okami, MD, Hiroshi Saito, MD The Annals of Thoracic Surgery Volume 98, Issue 4, Pages 1184-1191 (October 2014) DOI: 10.1016/j.athoracsur.2014.05.022 Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions

Fig 1 A schematic diagram depicting the Central Japan Lung Study Group (CJLSG) 0801. (CDDP = cisplatin; NSCLC = non-small cell lung cancer; PS = performance status; RT = radiation therapy; VNR = vinorelbine.) The Annals of Thoracic Surgery 2014 98, 1184-1191DOI: (10.1016/j.athoracsur.2014.05.022) Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions

Fig 2 The (A) overall and (B) progression-free survival curves from the day of the registration. The 2-year overall and progression-free survival rates were 85% and 71%, respectively. The Annals of Thoracic Surgery 2014 98, 1184-1191DOI: (10.1016/j.athoracsur.2014.05.022) Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions

Fig 3 The overall survival curves of patients stratified by their response to the induction chemoradiotherapy. No significant difference was seen between the two groups (p = 0.263), although patients with downstaged disease (solid line) seemed to have better survival than those who did not have downstaged disease (dashed line). The Annals of Thoracic Surgery 2014 98, 1184-1191DOI: (10.1016/j.athoracsur.2014.05.022) Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions